Skip To Main Content
Wichor M Bramer on Muck Rack

Wichor M Bramer

As seen in: Color Research & Application, Cambridge University Press & Assessment, Human Reproduction Update, Emergency Medicine Journal, Occupational and Environmental Medicine (OEM), Medscape, EClinicalMedicine, The World Bank Research Observer, Pain Research & Management, Reproductive BioMedicine Online and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Wichor M

Contact Wichor M, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The role of European HTA agencies in relation to the governance of medical technologies: a discourse analysis of academic literature

|
By Renée E Michels, Diana MJ Delnoij, Wichor M Bramer
| Cambridge University Press & Assessment
1. Background Health technology assessment (HTA) agencies play a role in the governance of certain health technologies, their scope varying by country and organisational mandate (Loblova, Reference Loblova2016; Sorenson and Chalkidou, Reference Sorenson and Chalkidou2012).
Open in Who Shared Issue with article?

How Do We Treat Children with Anterior Cutaneous Nerve Entrapment Syndrome and Is the Biopsychosocial Model Also Being Applied? A Scoping Review

|
By Wichor M Bramer, Maaike Dirckx
| Pain Research & Management Verified
Background. Evidence-based guidelines for managing anterior cutaneous nerve entrapment syndrome (ACNES) in children are absent. The primary aim of this review was to scrutinize the evidence supporting currently used treatment interventions.
Open in Who Shared Issue with article?

The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis

|
By Kazem Nasserinejad, Chantal Visser, Wichor M Bramer
| EClinicalMedicine Verified
Summary The optimal duration of anticoagulation in patients with active cancer and venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate anticoagulant therapy for 3–6 months and to continue anticoagulant therapy for as long as the cancer is active. However, an adequate systematic review on the rate of recurrent VTE after discontinuation of anticoagulant therapy has not been performed.
Open in Who Shared Issue with article?
See all 18 licensed articles (19 Total)